Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy

Erik Leidermark; Andreas Hallqvist; Lars Jacobsson; Per Karlsson; Erik Holmberg; Tom Bäck; Mia Johansson; Sture Lindegren; Stig Palm; Per Albertsson

doi:10.2967/jnumed.121.263349

Research ArticleClinical Investigation

Open Access

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with ²¹¹At Intraperitoneal Radioimmunotherapy

Erik Leidermark, Andreas Hallqvist, Lars Jacobsson, Per Karlsson, Erik Holmberg, Tom Bäck, Mia Johansson, Sture Lindegren, Stig Palm and Per Albertsson

Journal of Nuclear Medicine January 2023, 64 (1) 165-172; DOI: https://doi.org/10.2967/jnumed.121.263349

Erik Leidermark

1Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden;

2Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Andreas Hallqvist

1Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden;

3Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lars Jacobsson

2Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Per Karlsson

1Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden;

3Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Erik Holmberg

3Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and

4Regional Cancer Center West, Sahlgrenska University Hospital, Gothenburg, Sweden

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Tom Bäck

2Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mia Johansson

1Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden;

3Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sture Lindegren

2Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Stig Palm

2Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Per Albertsson

1Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden;

3Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 64, Issue 1

January 1, 2023

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Estimating the Risk for Secondary Cancer After Targeted α-Therapy with 211At Intraperitoneal Radioimmunotherapy

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with ²¹¹At Intraperitoneal Radioimmunotherapy

Erik Leidermark, Andreas Hallqvist, Lars Jacobsson, Per Karlsson, Erik Holmberg, Tom Bäck, Mia Johansson, Sture Lindegren, Stig Palm, Per Albertsson

Journal of Nuclear Medicine Jan 2023, 64 (1) 165-172; DOI: 10.2967/jnumed.121.263349

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with ²¹¹At Intraperitoneal Radioimmunotherapy

Erik Leidermark, Andreas Hallqvist, Lars Jacobsson, Per Karlsson, Erik Holmberg, Tom Bäck, Mia Johansson, Sture Lindegren, Stig Palm, Per Albertsson

Journal of Nuclear Medicine Jan 2023, 64 (1) 165-172; DOI: 10.2967/jnumed.121.263349

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy

Google Scholar

Keywords

secondary cancer
α-particle
targeted α-therapy
human
astatine-211
radium-224

Main menu

User menu

Search

Estimating the Risk for Secondary Cancer After Targeted α-Therapy with ²¹¹At Intraperitoneal Radioimmunotherapy

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords